Oncology Institute's Q1 Revenue Surges 41% to $147.4M, Net Loss Narrows to $2.5M
TOI has more than doubled off its 52-week low of $2.015.
Summary
Oncology Institute reported strong first-quarter 2026 results, with consolidated revenue surging 41.2% year-over-year to $147.4 million. The company significantly narrowed its net loss to $2.5 million, a substantial improvement from a $19.6 million loss in the prior-year quarter, and adjusted diluted EPS improved to $(0.02). These results continue the positive trajectory of revenue growth and loss reduction highlighted in the recent 2025 10-K, demonstrating solid operational progress. Management also reaffirmed full-year guidance and notably raised its free cash flow outlook, signaling increased confidence in future liquidity. This performance is a material positive development for the company's financial health and its path towards sustained profitability.
At the time of this announcement, TOI was trading at $4.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $402.3M. The 52-week trading range was $2.02 to $4.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.